The NEULARK study: can an investigational drug help to slow down Parkinson’s progression?

Genetic testing

• Completing a 10 minute online screening survey.

• If you pass the screening survey, you’ll be sent a saliva sample collection kit by Sano Genetics, a UK based biotechnology company. This will be posted to you with pre-paid return packaging. You'll use this kit to provide a saliva sample at home.

• This sample will be tested for changes in genes that mean that a protein linked to Parkinson's (called LRRK2) is working harder than it should.

• Everyone who takes part will receive their genetic results and have the option to schedule a session with a genetic counsellor to discuss the results. This could take up to 8 weeks. This test is for research use and not for use in diagnostic procedures. It will only indicate eligibility for referral to a clinical trial. 

• Those who may be eligible for the NEULARK study will be referred to their nearest trial site for full study screening.

The NEULARK study

• Over a period of 8 weeks, you’ll go through a thorough screening process to confirm you can take part.

• You’ll visit the trial site up to 19 times and have 1 phone call, with visits ranging from 1 to 6 hours. This includes check-ups and lab tests to monitor safety and how well the drug works.

• You’ll take the investigational drug or a placebo (like a sugar pill), and be asked to use a mobile app once daily for 52 weeks.

• You can also take part in an optional open label extension after the main study. This involves all participants receiving the investigational drug for an additional 26 weeks, 3 more trial site visits and 1 more phone call. 
Reasonable travel costs, meals, and accommodation related to the study visits will be reimbursed.

For more information, please read:
• the participant information sheet for genetic testing

• the participant information sheet for the NEULARK study